- Trials with a EudraCT protocol (393)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
393 result(s) found for: Infusion set.
Displaying page 1 of 20.
EudraCT Number: 2017-002374-39 | Sponsor Protocol Number: I8B-MC-ITSI | Start Date*: 2017-12-27 | |||||||||||
Sponsor Name:Lilly S.A. | |||||||||||||
Full Title: Protocol I8B-MC-ITSI A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro with an External Continuous Subcutaneous Insuli... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000726-21 | Sponsor Protocol Number: D4280C00006 | Start Date*: 2012-09-11 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant G... | ||||||||||||||||||
Medical condition: cUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) HU (Completed) IT (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005721-43 | Sponsor Protocol Number: D4280C00002 | Start Date*: 2012-05-14 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C... | ||
Medical condition: Complicated Urinary Tract Infections (cUTIs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) BE (Completed) BG (Completed) DE (Completed) CZ (Completed) SK (Completed) PT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002678-34 | Sponsor Protocol Number: AMLSG30-18 | Start Date*: 2019-08-06 |
Sponsor Name:University Hospital Ulm | ||
Full Title: Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics - AMLSG 30-18 | ||
Medical condition: Patients with newly diagnosed AML and intermediate- or adverse-risk genetics (according to 2017 ELN criteria), including AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML ac... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005722-21 | Sponsor Protocol Number: D4280C00004 | Start Date*: 2012-06-05 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C... | ||
Medical condition: Complicated Urinary Tract Infections (cUTIs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) DE (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) PL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004658-32 | Sponsor Protocol Number: BGB-A317-A1217-203 | Start Date*: 2021-06-03 |
Sponsor Name:BeiGene, Ltd. | ||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A... | ||
Medical condition: PD-L1 vCPS ≥ 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2013-004946-41 | Sponsor Protocol Number: s57223 | Start Date*: 2014-11-19 |
Sponsor Name:KULeuven | ||
Full Title: The influence of GLP-1 analog, liraglutide, on gastric accommodation, gastric emptying, hunger and the migrating motor complex in healthy volunteers | ||
Medical condition: healthy volunteers no medical condition; drug will be studied because it is known to influence gastric motility | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019249-25 | Sponsor Protocol Number: 981 | Start Date*: 2010-08-12 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: An open, prospective trial investigating pharmacokinetics and safety (Part A) of the human normal immunoglobulin for intravenous infusion (IVIG) BT090 and tolerability and safety of escalating infu... | |||||||||||||
Medical condition: Primary immunodeficiency disease (PID) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004656-14 | Sponsor Protocol Number: BGB-A317-A1217-301 | Start Date*: 2021-11-02 | |||||||||||
Sponsor Name:BeiGene, Ltd. | |||||||||||||
Full Title: Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizu... | |||||||||||||
Medical condition: Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Prematurely Ended) NL (Completed) PL (Completed) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003579-38 | Sponsor Protocol Number: APIDR_C_02083 | Start Date*: 2007-11-13 | |||||||||||
Sponsor Name:sanofi-aventis groupe | |||||||||||||
Full Title: Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Dia... | |||||||||||||
Medical condition: Type I Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SE (Completed) NL (Completed) AT (Completed) HU (Completed) IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000245-39 | Sponsor Protocol Number: BGB-A317-303 | Start Date*: 2018-06-21 | |||||||||||
Sponsor Name:BeiGene Ltd., c/o BeiGene USA Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti−PD1 Antibody) Compared with Docetaxel in Patients with Non−Small Cell Lung Cancer Who H... | |||||||||||||
Medical condition: Previously treated Non−Small Cell Lung Cancer in the second or third line setting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LT (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000833-35 | Sponsor Protocol Number: CRLX030A2201 | Start Date*: 2011-10-24 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, phase II, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure. | |||||||||||||
Medical condition: Acute Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001246-28 | Sponsor Protocol Number: P1200_14 | Start Date*: 2015-10-19 | |||||||||||
Sponsor Name:Cliniques Universitaires Saint-Luc, Université catholique de Louvain | |||||||||||||
Full Title: Ultrasound scores as imaging biomarkers of early response to subcutaneous tocilizumab in association with methotrexate in early rheumatoid arthritis (TOVERA study) | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006049-41 | Sponsor Protocol Number: TX 001/07 | Start Date*: 2008-02-07 |
Sponsor Name:Medizinische Universität Wien; Univ.Klin.f. Chirurgie; Klin. Abtlg. f. Transplantation | ||
Full Title: Evaluation of Tacrolimus (Prograf®) intraportal infusion during the implantation and the protective effect on ischemia-reperfusion injury in orthotopic liver transplant recipients - single center s... | ||
Medical condition: The effect of Tacrolimus (Prograf®) during the implantation on ischemia-reperfusion injury in orthotopic liver transplant recipients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-023226-20 | Sponsor Protocol Number: S52711 | Start Date*: 2010-11-24 |
Sponsor Name:KULeuven | ||
Full Title: Effect of the GLP-1 analogue liraglutide on intragastric pressure and satiation during nutrient drink infusion. | ||
Medical condition: healthy volunteers no medical condition; drugs will be studied because they are known to influence gastric motility. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001875-57 | Sponsor Protocol Number: 106524 | Start Date*: 2017-03-13 | |||||||||||||||||||||
Sponsor Name:Erasmus University Medical Center Rotterdam | |||||||||||||||||||||||
Full Title: Desmopressin and FVIII concentrate combination treatment in non-severe hemophilia A patients undergoing minor interventions | |||||||||||||||||||||||
Medical condition: Hemophilia A | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004154-22 | Sponsor Protocol Number: TR701-132 | Start Date*: 2014-04-17 | |||||||||||
Sponsor Name:Trius Therapeutics, a Wholly Owned Subsidiary of Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized Double-blind Study Comparing TR 701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia | |||||||||||||
Medical condition: Ventilated Gram-positive nosocomial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) AT (Completed) DE (Completed) BE (Completed) ES (Completed) GR (Completed) SK (Completed) CZ (Completed) EE (Completed) GB (Completed) HR (Completed) PT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000864-28 | Sponsor Protocol Number: DAP-PEDOST-11-03 | Start Date*: 2014-01-02 | |||||||||||||||||||||
Sponsor Name:Cubist Pharmaceuticals, LLC | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogeno... | |||||||||||||||||||||||
Medical condition: Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) IT (Completed) ES (Completed) GR (Completed) LV (Completed) GB (Completed) EE (Completed) BG (Completed) FR (Completed) SI (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004018-33 | Sponsor Protocol Number: PrefrontalCircuits | Start Date*: 2020-08-24 |
Sponsor Name:Department of Psychiatry and Psychotherapy, Medical University of Vienna | ||
Full Title: Prefrontal circuits for cognitive flexibility in an extradimensional set-shifting task for humans. | ||
Medical condition: Major depressive disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-007927-42 | Sponsor Protocol Number: Formula per TCI | Start Date*: 2007-09-20 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA | |||||||||||||
Full Title: Nessuna correzione vs nuova formula per limpostazione delle caratteristiche antropometriche per Target Controlled Infusion (TCI) di remifentanil in pazienti obesi. | |||||||||||||
Medical condition: Pazienti obesi ospedalizzati | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
